Mitochondrial Diseases

  • Maria Judit MolnarEmail author
  • Klara Pentelenyi
Part of the Advances in Predictive, Preventive and Personalised Medicine book series (APPPM, volume 6)


Mitochondrial diseases (prevalence 1:5,000) represent a heterogeneous group of multisystemic disorders which often affects skeletal muscle and nervous system and is mostly due to dysfunction of the mitochondrial respiratory chain. The tissues with the highest energy expenditure are the most vulnerable. The disorders are caused either by mutations of mtDNA, or nDNA. A special group of the mitochondrial disorders is the defect of intergenomic communication disturbancy which affects the mtDNA quantitatively (mtDNA depletion) or qualitatively (multiple mtDNA deletion). Owing to the unequal distribution of mitochondria in the different tissues and the co-existence of mutant and wild type mtDNA, these disorders may present with a huge variety of symptoms, making diagnosis difficult. In every year about ten new disease-causing genes are discovered. In the diagnosis of the mitochondrial disorders the muscle histology and the molecular biology play the most important role. Identification of the disease causing mutations may help to select the most effective therapy. E.g. ketogenic diet is effective mostly in pyruvate dehydrogenase deficiency, valproate should be avoided in cases with special SNPs in the POLG1 gene. In summary: the molecular stratification of the mitochondrial disorders is very important in the predictive and preventive treatment of this rare disease group.


Mitochondrial disease mtDNA disorders Intergenomial communication Gene therapy Heteroplasmy Supplementation therapy Sirtuin EPI-743 Predictive, preventive and personalized medicine 



MJM and KP was supported by the grant KTIA_AIK_12-1-2013-0017.


  1. 1.
    Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B (1962) A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 41:1776–1804PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF (2004) The epidemiology of mitochondrial disorders – past, present and future. Biochim Biophys Acta 1659:115–120PubMedCrossRefGoogle Scholar
  3. 3.
    Saneto RP, Sedensky MM (2013) Mitochondrial disease in childhood: mtDNA encoded. Neurotherapeutics 10:199–211. doi: 10.1007/s13311-012-0167-0 PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    DiMauro S, Hirano M (2005) Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 15:276–286PubMedCrossRefGoogle Scholar
  5. 5.
    Shoubridge E, Molnar MJ (2002) Structural and molecular basis of skeletal muscle diseases. ISN Neuropathology Press, BaselGoogle Scholar
  6. 6.
    Calvo S, Jain M, Xie X, Sheth SA, Chang B, Goldberger OA, Spinazzola A, Zeviani M, Carr SA, Mootha VK (2006) Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet 38:576–582PubMedCrossRefGoogle Scholar
  7. 7.
    Molnar MJ (2010) Further mitochondrial cytopathies. In: Kazazian HH Jr, Klein G, Moser HW, Orkin SH, Roizman B, Thakker V, Watkins H (eds) Encyclopedia of molecular medicine. Wiley, New YorkGoogle Scholar
  8. 8.
    Goldstein A, Bhatia P, Vento JM (2013) Mitochondrial disease in childhood: nuclear encoded. Neurotherapeutics 10:212–226. doi: 10.1007/s13311-013-0185-6 PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Wong CL-J (2010) Molecular genetics of mitochondrial disorders. Dev Disabil Res Rev 16:154–162. doi: 10.1002/ddrr.104 PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen BH (2013) Neuromuscular and systematic presentations in adults: diagnosed beyond MERRF and MELAS. Neurotherapeutics 10:227–242. doi: 10.1007/s13311-013-0188-3 PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, Laskowski A, Garone C, Liu S, Jaffe DB, Christodoulou J, Fletcher JM, Bruno DL, Goldblatt J, Dimauro S, Thorburn DR, Mootha VK (2012) Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med 4:118ra10. doi: 10.1126/scitranslmed.3003310 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Mao CC, Holt IJ (2009) Clinical and molecular aspects of diseases of mitochondrial DNA instability. Chang Gung Med J 32:354–369PubMedGoogle Scholar
  13. 13.
    Goldstein A, Wolfe LA (2013) The elusive magic pill: finding effective therapies for mitochondrial disorders. Neurotherapeutics 10:320–328. doi: 10.1007/s13311-012-0175-0 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Institute of Genomic Medicine and Rare DisordersSemmelweis UniversityBudapestHungary

Personalised recommendations